Browse PICALM

Summary
SymbolPICALM
Namephosphatidylinositol binding clathrin assembly protein
Aliases CLTH; clathrin assembly lymphoid myeloid leukemia protein; Phosphatidylinositol-binding clathrin assembly pr ......
Chromosomal Location11q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane, clathrin-coated pit Golgi apparatus Cytoplasmic vesicle, clathrin-coated vesicle Nucleus Note=Colocalized with clathrin in the Golgi area (PubMed:10436022). Interaction with PIMREG may target PICALM to the nucleus in some cells (PubMed:16491119).
Domain PF07651 ANTH domain
Function

Assembly protein recruiting clathrin and adapter protein complex 2 (AP2) to cell membranes at sites of coated-pit formation and clathrin-vesicle assembly. May be required to determine the amount of membrane to be recycled, possibly by regulating the size of the clathrin cage. Involved in AP2-dependent clathrin-mediated endocytosis at the neuromuscular junction.

> Gene Ontology
 
Biological Process GO:0000041 transition metal ion transport
GO:0006826 iron ion transport
GO:0006898 receptor-mediated endocytosis
GO:0007034 vacuolar transport
GO:0007409 axonogenesis
GO:0010466 negative regulation of peptidase activity
GO:0010951 negative regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0016050 vesicle organization
GO:0016188 synaptic vesicle maturation
GO:0016197 endosomal transport
GO:0016358 dendrite development
GO:0021700 developmental maturation
GO:0030100 regulation of endocytosis
GO:0031623 receptor internalization
GO:0034205 beta-amyloid formation
GO:0034248 regulation of cellular amide metabolic process
GO:0034250 positive regulation of cellular amide metabolic process
GO:0035459 cargo loading into vesicle
GO:0042982 amyloid precursor protein metabolic process
GO:0042987 amyloid precursor protein catabolic process
GO:0043112 receptor metabolic process
GO:0045806 negative regulation of endocytosis
GO:0045861 negative regulation of proteolysis
GO:0045862 positive regulation of proteolysis
GO:0048259 regulation of receptor-mediated endocytosis
GO:0048261 negative regulation of receptor-mediated endocytosis
GO:0048268 clathrin coat assembly
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048813 dendrite morphogenesis
GO:0050435 beta-amyloid metabolic process
GO:0051051 negative regulation of transport
GO:0051346 negative regulation of hydrolase activity
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0055072 iron ion homeostasis
GO:0055076 transition metal ion homeostasis
GO:0060627 regulation of vesicle-mediated transport
GO:0061564 axon development
GO:0070997 neuron death
GO:0072583 clathrin-dependent endocytosis
GO:0097286 iron ion import
GO:0097459 iron ion import into cell
GO:0098657 import into cell
GO:0098659 inorganic cation import into cell
GO:0099587 inorganic ion import into cell
GO:1901214 regulation of neuron death
GO:1901216 positive regulation of neuron death
GO:1902003 regulation of beta-amyloid formation
GO:1902004 positive regulation of beta-amyloid formation
GO:1902959 regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process
GO:1902961 positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process
GO:1902962 regulation of metalloendopeptidase activity involved in amyloid precursor protein catabolic process
GO:1902963 negative regulation of metalloendopeptidase activity involved in amyloid precursor protein catabolic process
GO:1902991 regulation of amyloid precursor protein catabolic process
GO:1902992 negative regulation of amyloid precursor protein catabolic process
GO:1902993 positive regulation of amyloid precursor protein catabolic process
GO:1904683 regulation of metalloendopeptidase activity
GO:1904684 negative regulation of metalloendopeptidase activity
GO:1905048 regulation of metallopeptidase activity
GO:1905049 negative regulation of metallopeptidase activity
GO:1905245 regulation of aspartic-type peptidase activity
GO:1905247 positive regulation of aspartic-type peptidase activity
Molecular Function GO:0005543 phospholipid binding
GO:0005545 1-phosphatidylinositol binding
GO:0030276 clathrin binding
GO:0030674 protein binding, bridging
GO:0032050 clathrin heavy chain binding
GO:0035091 phosphatidylinositol binding
GO:0035615 clathrin adaptor activity
GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0060090 binding, bridging
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
GO:0098748 endocytic adaptor activity
Cellular Component GO:0005905 clathrin-coated pit
GO:0005913 cell-cell adherens junction
GO:0016234 inclusion body
GO:0030117 membrane coat
GO:0030118 clathrin coat
GO:0030119 AP-type membrane coat adaptor complex
GO:0030120 vesicle coat
GO:0030122 AP-2 adaptor complex
GO:0030125 clathrin vesicle coat
GO:0030128 clathrin coat of endocytic vesicle
GO:0030131 clathrin adaptor complex
GO:0030132 clathrin coat of coated pit
GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0030665 clathrin-coated vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0030669 clathrin-coated endocytic vesicle membrane
GO:0042734 presynaptic membrane
GO:0043025 neuronal cell body
GO:0044297 cell body
GO:0045211 postsynaptic membrane
GO:0045334 clathrin-coated endocytic vesicle
GO:0048475 coated membrane
GO:0097060 synaptic membrane
GO:0097418 neurofibrillary tangle
GO:0098589 membrane region
GO:0098793 presynapse
GO:0098794 postsynapse
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-8856825: Cargo recognition for clathrin-mediated endocytosis
R-HSA-421837: Clathrin derived vesicle budding
R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-432722: Golgi Associated Vesicle Biogenesis
R-HSA-199991: Membrane Trafficking
R-HSA-5653656: Vesicle-mediated transport
R-HSA-199992: trans-Golgi Network Vesicle Budding
Summary
SymbolPICALM
Namephosphatidylinositol binding clathrin assembly protein
Aliases CLTH; clathrin assembly lymphoid myeloid leukemia protein; Phosphatidylinositol-binding clathrin assembly pr ......
Chromosomal Location11q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PICALM and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPICALM
Namephosphatidylinositol binding clathrin assembly protein
Aliases CLTH; clathrin assembly lymphoid myeloid leukemia protein; Phosphatidylinositol-binding clathrin assembly pr ......
Chromosomal Location11q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PICALM in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.55 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPICALM
Namephosphatidylinositol binding clathrin assembly protein
Aliases CLTH; clathrin assembly lymphoid myeloid leukemia protein; Phosphatidylinositol-binding clathrin assembly pr ......
Chromosomal Location11q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PICALM in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2460.315
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1710.948
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3040.871
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1220.765
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6070.787
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4960.867
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2640.589
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0350.987
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5110.836
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3610.866
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8970.783
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0540.349
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PICALM in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPICALM
Namephosphatidylinositol binding clathrin assembly protein
Aliases CLTH; clathrin assembly lymphoid myeloid leukemia protein; Phosphatidylinositol-binding clathrin assembly pr ......
Chromosomal Location11q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PICALM. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPICALM
Namephosphatidylinositol binding clathrin assembly protein
Aliases CLTH; clathrin assembly lymphoid myeloid leukemia protein; Phosphatidylinositol-binding clathrin assembly pr ......
Chromosomal Location11q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PICALM. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PICALM.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPICALM
Namephosphatidylinositol binding clathrin assembly protein
Aliases CLTH; clathrin assembly lymphoid myeloid leukemia protein; Phosphatidylinositol-binding clathrin assembly pr ......
Chromosomal Location11q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PICALM. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPICALM
Namephosphatidylinositol binding clathrin assembly protein
Aliases CLTH; clathrin assembly lymphoid myeloid leukemia protein; Phosphatidylinositol-binding clathrin assembly pr ......
Chromosomal Location11q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PICALM expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPICALM
Namephosphatidylinositol binding clathrin assembly protein
Aliases CLTH; clathrin assembly lymphoid myeloid leukemia protein; Phosphatidylinositol-binding clathrin assembly pr ......
Chromosomal Location11q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PICALM and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPICALM
Namephosphatidylinositol binding clathrin assembly protein
Aliases CLTH; clathrin assembly lymphoid myeloid leukemia protein; Phosphatidylinositol-binding clathrin assembly pr ......
Chromosomal Location11q14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PICALM collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.